FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385498048> ?p ?o ?g. }

• W4385498048 abstract "Anti-thymocyte globulin (ATG) is currently the most widely prescribed induction regimen for preventing acute rejection after solid organ transplantation. However, the optimal dose of ATG induction regimen in Asian kidney recipients is unclear. Using the Korean Organ Transplantation Registry, we performed a retrospective cohort study of 4579 adult patients who received renal transplantation in South Korea and divided them into three groups according to the induction regimen: basiliximab group (n = 3655), low-dose ATG group (≤ 4.5 mg/kg; n = 467), and high-dose ATG group (> 4.5 mg/kg; n = 457). We applied the Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG) package to generate high-quality propensity score weights for intergroup comparisons. During four-year follow-ups, the high-dose ATG group had the highest biopsy-proven acute rejection rate (basiliximab 20.8% vs. low-dose ATG 22.4% vs. high-dose ATG 25.6%; P < 0.001). However, the rates of overall graft failure (4.0% vs. 5.0% vs. 2.6%; P < 0.001) and mortality (1.7% vs. 2.8% vs. 1.0%; P < 0.001) were the lowest in the high-dose ATG group. Our results show that high-dose ATG induction (> 4.5 mg/kg) was superior to basiliximab and low-dose ATG induction in terms of graft and patient survival in Asian patients undergoing kidney transplant." @default.
• W4385498048 created "2023-08-03" @default.
• W4385498048 creator A5003144230 @default.
• W4385498048 creator A5007580413 @default.
• W4385498048 creator A5008101143 @default.
• W4385498048 creator A5008666758 @default.
• W4385498048 creator A5010730182 @default.
• W4385498048 creator A5012749837 @default.
• W4385498048 creator A5013175108 @default.
• W4385498048 creator A5017943773 @default.
• W4385498048 creator A5018472878 @default.
• W4385498048 creator A5018763027 @default.
• W4385498048 creator A5023374702 @default.
• W4385498048 creator A5025168962 @default.
• W4385498048 creator A5026681307 @default.
• W4385498048 creator A5028024742 @default.
• W4385498048 creator A5029416594 @default.
• W4385498048 creator A5032705623 @default.
• W4385498048 creator A5033574471 @default.
• W4385498048 creator A5033725310 @default.
• W4385498048 creator A5034020304 @default.
• W4385498048 creator A5037395158 @default.
• W4385498048 creator A5038255406 @default.
• W4385498048 creator A5040859854 @default.
• W4385498048 creator A5041796084 @default.
• W4385498048 creator A5044011561 @default.
• W4385498048 creator A5046005727 @default.
• W4385498048 creator A5046560722 @default.
• W4385498048 creator A5049594721 @default.
• W4385498048 creator A5049872669 @default.
• W4385498048 creator A5052328556 @default.
• W4385498048 creator A5055682520 @default.
• W4385498048 creator A5056237368 @default.
• W4385498048 creator A5058826981 @default.
• W4385498048 creator A5059260618 @default.
• W4385498048 creator A5066643229 @default.
• W4385498048 creator A5066860578 @default.
• W4385498048 creator A5067237923 @default.
• W4385498048 creator A5070374265 @default.
• W4385498048 creator A5072340815 @default.
• W4385498048 creator A5073203839 @default.
• W4385498048 creator A5077749755 @default.
• W4385498048 creator A5080009275 @default.
• W4385498048 creator A5080615622 @default.
• W4385498048 creator A5081381297 @default.
• W4385498048 creator A5081578294 @default.
• W4385498048 creator A5087912793 @default.
• W4385498048 creator A5090051835 @default.
• W4385498048 creator A5091642232 @default.
• W4385498048 date "2023-08-02" @default.
• W4385498048 modified "2023-09-26" @default.
• W4385498048 title "Evaluating anti-thymocyte globulin induction doses for better allograft and patient survival in Asian kidney transplant recipients" @default.
• W4385498048 cites W1496154285 @default.
• W4385498048 cites W1916860342 @default.
• W4385498048 cites W1971278669 @default.
• W4385498048 cites W1981435382 @default.
• W4385498048 cites W1988034903 @default.
• W4385498048 cites W1996834922 @default.
• W4385498048 cites W1999298846 @default.
• W4385498048 cites W2000138932 @default.
• W4385498048 cites W2000531481 @default.
• W4385498048 cites W2020650912 @default.
• W4385498048 cites W2026860062 @default.
• W4385498048 cites W2046753653 @default.
• W4385498048 cites W2056071158 @default.
• W4385498048 cites W2063759059 @default.
• W4385498048 cites W2069726523 @default.
• W4385498048 cites W2072651170 @default.
• W4385498048 cites W2082111678 @default.
• W4385498048 cites W2108648204 @default.
• W4385498048 cites W2135136335 @default.
• W4385498048 cites W2164249320 @default.
• W4385498048 cites W2170783570 @default.
• W4385498048 cites W2314905526 @default.
• W4385498048 cites W2552263672 @default.
• W4385498048 cites W2733068461 @default.
• W4385498048 cites W2899041044 @default.
• W4385498048 cites W2945882587 @default.
• W4385498048 cites W3045748193 @default.
• W4385498048 cites W3162233763 @default.
• W4385498048 cites W4205420254 @default.
• W4385498048 cites W4253750716 @default.
• W4385498048 cites W4322719909 @default.
• W4385498048 doi "https://doi.org/10.1038/s41598-023-39353-6" @default.
• W4385498048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37532735" @default.
• W4385498048 hasPublicationYear "2023" @default.
• W4385498048 type Work @default.
• W4385498048 citedByCount "0" @default.
• W4385498048 crossrefType "journal-article" @default.
• W4385498048 hasAuthorship W4385498048A5003144230 @default.
• W4385498048 hasAuthorship W4385498048A5007580413 @default.
• W4385498048 hasAuthorship W4385498048A5008101143 @default.
• W4385498048 hasAuthorship W4385498048A5008666758 @default.
• W4385498048 hasAuthorship W4385498048A5010730182 @default.
• W4385498048 hasAuthorship W4385498048A5012749837 @default.
• W4385498048 hasAuthorship W4385498048A5013175108 @default.
• W4385498048 hasAuthorship W4385498048A5017943773 @default.
• W4385498048 hasAuthorship W4385498048A5018472878 @default.
• W4385498048 hasAuthorship W4385498048A5018763027 @default.
• W4385498048 hasAuthorship W4385498048A5023374702 @default.

• next